This conference will explore new or improved therapeutic approaches for finding cures for diseases which traditionally have been difficult to treat. This includes technologies for optimizing treatments and monitoring efficacy based on insights into cell and tissue state, circuitry, behavior, function, and responsiveness in normal and disease states, biomarker detection, better methods to predict and track efficacy, and enhanced manufacturing capabilities.
Daikin’s Open Innovation Lab invites startups of all stages and from all over the world to submit ideas and insights to collaborate and help develop solutions that can provide HVAC services and solutions fit for the remote/hybrid working world amid the current pandemic environment and thereafter.
Procter & Gamble is looking for new approaches and technologies that can help them to apply Generative AI to radically disrupt the efficiency and effectiveness of P&G brand building communication.
Intel Ignite is Intel’s global growth program for early-stage, deep-tech startups. Intel Ignite is now taking applications for the newest cohort of “Ignite Boston(US): Batch #1” that kicks off this Fall.
P&G is looking for partners and solutions that can assist them to optimize their supply chain by improving their back-office operations and order-to-cash cycle through touchless order acquisition solutions. Additionally, P&G would like to understand existing best practices in the e-Commerce industry to improve their own existing processes. P&G is specifically looking for partners and solutions that are able to execute pilots in the Asia, Middle East & Africa region.
Advanced Tools for Understanding Single-Cell Genomics and Advancing Cellular and Precision Medicines
MIT Startup Exchange presents its September Startup Workshop, centered around real-world IoT and edge computing. Many companies are grappling with how to use IoT and data/AI in their organization to monitor, predict, improve, and transform what they do. Meanwhile, many MIT startups are developing and providing innovative technology solutions to answer these very questions for industry. This workshop will present perspectives from industry leaders, academics, and corporate investors, while also showcasing select MIT startups in the field.
AI Driven Bloodless Blood Tests Sean (Shunsuke) Matsuoka, Co-Founder & COO, GPx GPx: https://gpx.ai/
In an aging society, the number of heart failure patients is increasing, making the prevention of readmissions and reduction of medical costs critical issues. Remote monitoring using invasive implantable devices has proven effective in reducing heart failure readmissions, but its use remains limited.
To address this, GPx has developed an algorithm that non-invasively predicts signs of heart failure exacerbation. This algorithm was created using clinical trial data from monitoring 245 heart failure patients over 6 months to a year at eight facilities, including the Mayo Clinic in the U.S. The algorithm links digital biomarker data with vital blood tests (NT-proBNP and creatinine) to achieve high-precision prediction and early medical intervention.
Additionally, with a grant of 1.2 billion yen provided through AMED, we are collaborating with the National Cerebral and Cardiovascular Center (Dr. Chisato Izumi) to conduct a clinical trial involving 400 patients starting April 2025. The trial will be conducted at the National Cerebral and Cardiovascular Center, Kyoto University, Kobe University, and Kochi University.
Furthermore, at this year's MIT Japan Conference, we will unveil a groundbreaking point-of-care (POC) potassium testing device for the first time. At the conference, we aim to explore the feasibility of applying our technology to other conditions (such as kidney failure, pulmonary arterial hypertension, and cardio-oncology) and to assess the potential for providing algorithm-based services for heart failure patients within Japan.